Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    hn002
Previous Study | Return to List | Next Study

Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02254278
Recruitment Status : Active, not recruiting
First Posted : October 1, 2014
Results First Posted : August 12, 2020
Last Update Posted : January 22, 2021
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
NRG Oncology

Tracking Information
First Submitted Date  ICMJE September 29, 2014
First Posted Date  ICMJE October 1, 2014
Results First Submitted Date  ICMJE June 25, 2020
Results First Posted Date  ICMJE August 12, 2020
Last Update Posted Date January 22, 2021
Study Start Date  ICMJE October 2014
Actual Primary Completion Date June 10, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 28, 2020)
Percentage of Participants Alive Without Progression at Two Years (Progression-free Survival) [ Time Frame: From randomization to 2 years ]
Progression is defined as local, regional, or distant disease progression or death due to any cause. Percentage is estimated using the binomial distribution.
Original Primary Outcome Measures  ICMJE
 (submitted: September 29, 2014)
PFS [ Time Frame: Time of randomization to local-regional failure, distant metastasis, or death due to any causes, assessed at 2 years ]
PFS rates will be estimated for all treatment arms using the Kaplan-Meier method. One sample binomial test will be used to test the 2-year PFS for each arm. Multivariate analysis will be performed using the Cox proportional hazards model.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 28, 2020)
  • Percentage of Participants With Local-regional Failure [ Time Frame: From randomization to 2 years ]
    Local-regional failure is defined as local or regional progression, salvage surgery of the primary tumor with tumor present/unknown, salvage neck dissection with tumor present/unknown > 20 weeks after the end of radiation therapy, death due to study cancer without documented progression, or death due to unknown causes without documented progression. Distant metastasis and death due to other causes are considered competing risks. Local-regional failure time is defined as time from randomization to the date of first progression/death or last known follow-up (censored). Rates are estimated by the cumulative incidence method.
  • Percentage of Participants With Distant Metastasis [ Time Frame: From randomization to 2 years ]
    Distant metastasis is defined as distant progression. Local-regional failure and death due to any cause are considered competing risks. Distant metastasis time is defined as time from randomization to the date of progression/death or last known follow-up (censored). Rates are estimated by the cumulative incidence method.
  • Percentage of Participants Alive [ Time Frame: from randomization to 2 years ]
    Overall survival time is defined as time from randomization to the date of death or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method.
  • Percentage of Participants With Grade 3+ Adverse Events [ Time Frame: End of radiation therapy (RT) (approximately 6 weeks for Arm 1 and 5 weeks for Arm 2), then 1 month, 6 months, 1 year, and two years after end of RT ]
    Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE.
  • Mean One-year Total MD Anderson Dysphagia Inventory (MDADI) Score (Patient-reported Swallowing Outcome) [ Time Frame: One year post-RT. Radiation therapy (RT) ends at approximately 6 weeks for Arm 1 and 5 weeks for Arm 2 ]
    The MDADI is a 20-item tool with each item scored as Strongly agree; Agree; No opinion; Disagree; or Strongly disagree. There is 1 global item (G1), 6 emotional subscale items (E2-E7), 5 functional subscale items (F1-F5), and 8 physical subscale items (P1-P8). For all items except E7 and F2, Strongly agree corresponds to a score of 1, Agree 2, No opinion 3, Disagree 4, and Strongly disagree 5. For E7 and F2, the scores are reversed; these 2 items are rescored to match the others before calculating summary scores. The composite (total) score is the mean of the 19 items (other than G1) X 20. Composite scores range from 20 to 100 with higher scores indicating less dysphagia.
  • Negative Predictive Value (NPV) of Post-treatment FDG-PET/CT Scan [Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT)] for Progression-free Survival and Local-regional Control at Two Years [ Time Frame: 3 months (scan) and two years after the end of RT (approximately 6 weeks for Arm 1 and 5 weeks for Arm 2) ]
    NPV is the percentage of participants alive and failure-free at 2 years among those with a negative post-treatment scan, as evaluated by central review. Negative scan determined as follows: primary site, right neck, left neck evaluated using a 5-point ordinal scale: 1-Definite complete metabolic response (CMR), 2-Likely CMR, 3-Likely inflammatory, 4-Likely residual metabolic disease (RMD), and 5-Definite RMD. 'Negative'= 1 or 2, 'Indeterminate'=3, 'Positive' = 4 or 5. 'Negative' for all three evaluation sites = overall score of 'Negative.' Progression (failure) is defined as local, regional, or distant disease progression (PR) or any death. Local-regional progression (failure) is defined as local or regional PR, salvage surgery of the primary tumor with tumor present/unknown, salvage neck dissection with tumor present/unknown > 20 weeks post RT, death due to study cancer or unknown causes without documented PR. The protocol specified that both arms would be combined for analysis.
  • Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Detection Rate [ Time Frame: Baseline to up to 2 weeks after the completion of treatment ]
    With a two-sided type error rate of 5% and based on chi-squared test for proportions, there is a greater than 99% power to detect HPV DNA detection rate of 65% and 95% between the 2 groups (n=140 in each arm). The rate of detection for each group will be summarized based on binomial distributions and a 95% confidence intervals (CI) will be provided.
  • HPV DNA Rate Decline [ Time Frame: Baseline to up to 2 weeks after the completion of treatment ]
    With a two-sided type error rate of 5% and based on paired t test for means, there is 99% power to detect HPV DNA rate decline of 0.375 (effect size) within each arm (n=140). The HPV DNA rate for each group will be summarized using means and standard deviations.
  • HPV DNA Copy Number [ Time Frame: Baseline to up to 2 weeks after the completion of treatment ]
    Correlation between HPV DNA copy number and the nodal metabolic volume will be calculated using Spearman's correlation coefficient and R2, and the corresponding 95% CI will be provided.
  • Variance for HPV DNA [ Time Frame: Baseline to up to 2 weeks after the completion of treatment ]
    Univariable and multivariable cause specific analysis will be performed using the Cox proportional hazards model for rate of relapse.
Original Secondary Outcome Measures  ICMJE
 (submitted: September 29, 2014)
  • Local-regional failure [ Time Frame: At 6 months ]
    The failure rates for the experimental treatment will be compared against the control using a log rank test. The cumulative incidence method will be used to estimate locoregional and distant failure rates and the failure rates for the experimental treatment will be compared against the control using a failure specific log rank test. Multivariate analysis will be performed using the Cox proportional hazards model.
  • Local-regional failure [ Time Frame: At 2 years ]
    The failure rates for the experimental treatment will be compared against the control using a log rank test. The cumulative incidence method will be used to estimate locoregional and distant failure rates and the failure rates for the experimental treatment will be compared against the control using a failure specific log rank test. Multivariate analysis will be performed using the Cox proportional hazards model.
  • Distant metastasis [ Time Frame: At 6 months ]
    The cumulative incidence method will be used to estimate locoregional and distant failure rates and the failure rates for the experimental treatment will be compared against the control using a failure specific log rank test. Multivariate analysis will be performed using the Cox proportional hazards model.
  • Distant metastasis [ Time Frame: At 2 years ]
    The cumulative incidence method will be used to estimate locoregional and distant failure rates and the failure rates for the experimental treatment will be compared against the control using a failure specific log rank test. Multivariate analysis will be performed using the Cox proportional hazards model.
  • Overall survival [ Time Frame: At 6 months ]
    Will be estimated using the Kaplan-Meier method.
  • Overall survival [ Time Frame: At 2 years ]
    Will be estimated using the Kaplan-Meier method.
  • Incidence of acute toxicities (>= grade 3, Common Terminology Criteria for Adverse Events [CTCAE], version [v].4) [ Time Frame: At 6 weeks ]
    Rates of adverse events (>= grade 3, CTCAE, v.4) for acute toxicities will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test between the 2 treatment arms.
  • Incidence of acute toxicities (>= grade 3, CTCAE, v.4) [ Time Frame: At 1 month ]
    Rates of adverse events (>= grade 3, CTCAE, v.4) for acute toxicities will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test between the 2 treatment arms.
  • Incidence of acute toxicities (>= grade 3, CTCAE, v.4) [ Time Frame: At 6 months ]
    Rates of adverse events (>= grade 3, CTCAE, v.4) for acute toxicities will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test between the 2 treatment arms.
  • Incidence of late toxicities (>= grade 3, CTCAE, v.4) [ Time Frame: At 1 year ]
    Rates of adverse events (>= grade 3, CTCAE, v.4) for late toxicities will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test between the 2 treatment arms.
  • Incidence of late toxicities (>= grade 3, CTCAE, v.4) [ Time Frame: At 2 years ]
    Rates of adverse events (>= grade 3, CTCAE, v.4) for late toxicities will be estimated using a binomial distribution along with their associated 95% confidence intervals and will be compared using Fisher's exact test between the 2 treatment arms.
  • Patient-reported swallowing outcomes as measured by the change in total MDADI score [ Time Frame: Baseline to up to 6 months ]
    Correlation between MDADI and dysphagia as well as other variables will be calculated using Spearman's correlation coefficient and the corresponding p values will be reported. Correlation between categorical measures will be summarized by odds ratios, chi square tests, and associated measures. Adjusted correlation may be derived from analysis of covariance (ANCOVA) models or derived directly using nonparametric analysis of variance (ANOVA) models if normality assumption is violated. If comparison to historical control is needed, a one-sample t test will be utilized.
  • Patient-reported swallowing outcomes as assessed by the mean individual change in total MDADI score [ Time Frame: Baseline to up to 1 year ]
    Correlation between MDADI and dysphagia as well as other variables will be calculated using Spearman's correlation coefficient and the corresponding p values will be reported. Correlation between categorical measures will be summarized by odds ratios, chi square tests, and associated measures. Adjusted correlation may be derived from ANCOVA models or derived directly using nonparametric ANOVA models if normality assumption is violated. If comparison to historical control is needed, a one-sample t test will be utilized.
  • Patient-reported swallowing outcomes as assessed by the mean individual change in total MDADI score [ Time Frame: Baseline to up to 2 years ]
    Correlation between MDADI and dysphagia as well as other variables will be calculated using Spearman's correlation coefficient and the corresponding p values will be reported. Correlation between categorical measures will be summarized by odds ratios, chi square tests, and associated measures. Adjusted correlation may be derived from ANCOVA models or derived directly using nonparametric ANOVA models if normality assumption is violated. If comparison to historical control is needed, a one-sample t test will be utilized.
  • Negative predictive value (NPV) of FDG-PET/CT [ Time Frame: 12-14 weeks post-therapy ]
    The power is calculated to detect a minimum difference of 3% between the NPV under the null hypothesis of 90%-92% and the NPV under the alternative hypothesis of 93-95% using a one-sided Z-test at a significance level of 0.05.
  • Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Detection Rate [ Time Frame: Baseline to up to 2 weeks after the completion of treatment ]
    With a two-sided type error rate of 5% and based on chi-squared test for proportions, there is a greater than 99% power to detect HPV DNA detection rate of 65% and 95% between the 2 groups (n=140 in each arm). The rate of detection for each group will be summarized based on binomial distributions and a 95% confidence intervals (CI) will be provided.
  • HPV DNA Copy Number [ Time Frame: Baseline to up to 2 weeks after the completion of treatment ]
    Correlation between HPV DNA copy number and the nodal metabolic volume will be calculated using Spearman's correlation coefficient and R2, and the corresponding 95% CI will be provided.
  • HPV DNA Rate Decline [ Time Frame: Baseline to up to 2 weeks after the completion of treatment ]
    With a two-sided type error rate of 5% and based on paired t test for means, there is 99% power to detect HPV DNA rate decline of 0.375 (effect size) within each arm (n=140). The HPV DNA rate for each group will be summarized using means and standard deviations.
  • Variance for HPV DNA [ Time Frame: Baseline to up to 2 weeks after the completion of treatment ]
    Univariable and multivariable cause specific analysis will be performed using the Cox proportional hazards model for rate of relapse.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
Official Title  ICMJE A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Brief Summary This randomized phase II trial studies the side effects and how well modestly reduced-dose intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating patients with oropharyngeal cancer that has spread to other places in the body (advanced). Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether IMRT is more effective with or without cisplatin in treating patients with oropharyngeal cancer.
Detailed Description

PRIMARY OBJECTIVES:

-To select the arm(s) achieving a 2-year progression-free survival rate of >= 85% without unacceptable swallowing toxicity at 1 year.

SECONDARY OBJECTIVES:

  • To determine patterns of failure (locoregional relapse versus distant) and survival -(overall and progression-free) at 6 months and 2 years.
  • To determine acute toxicity profiles at the end of radiation therapy and at 1 and 6 months.
  • To determine late toxicity profiles at 1 and 2 years.
  • To determine patient-reported swallowing outcomes at 6 months and 1 and 2 years.
  • To determine the predictive value of 12-14 week, post-treatment fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) for locoregional control and progression free survival (PFS) at 2 years.
  • To determine the predictive value of blood and tissue biomarkers for disease outcomes at 2 years.
  • To determine swallowing recovery per videofluoroscopy imaging at 2 years.

After completion of study treatment, patients are followed at 1 and 3 months then every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Stage III Oropharyngeal Squamous Cell Carcinoma
  • Stage IVA Oropharyngeal Squamous Cell Carcinoma
  • Stage IVB Oropharyngeal Squamous Cell Carcinoma
  • Stage IVC Oropharyngeal Squamous Cell Carcinoma
  • Tongue Carcinoma
Intervention  ICMJE
  • Drug: Cisplatin
    40 mg/m2 IV (intravenously) weekly for 6 weeks
  • Radiation: IMRT 6 weeks
    Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy
    Other Name: Intensity-Modulated Radiotherapy
  • Radiation: IMRT 5 weeks
    Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy
    Other Name: Intensity-Modulated Radiotherapy
Study Arms  ICMJE
  • Experimental: IMRT 6 weeks + cisplatin
    IMRT 6 weeks with concurrent cisplatin
    Interventions:
    • Drug: Cisplatin
    • Radiation: IMRT 6 weeks
  • Experimental: IMRT 5 weeks
    IMRT 5 weeks
    Intervention: Radiation: IMRT 5 weeks
Publications * Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, Truong MT, Kong C, Jordan R, Subramaniam RM, Yao M, Chung CH, Geiger JL, Chan JW, O'Sullivan B, Blakaj DM, Mell LK, Thorstad WL, Jones CU, Banerjee RN, Lominska C, Le QT. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). J Clin Oncol. 2021 Mar 20;39(9):956-965. doi: 10.1200/JCO.20.03128. Epub 2021 Jan 28.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: July 28, 2020)
316
Original Estimated Enrollment  ICMJE
 (submitted: September 29, 2014)
296
Estimated Study Completion Date  ICMJE May 31, 2024
Actual Primary Completion Date June 10, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

Step 1: Registration:

  1. Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls); cytologic diagnosis from a cervical lymph node is sufficient in the presence of clinical evidence of a primary tumor in the oropharynx. Clinical evidence should be documented, may consist of palpation, imaging, or endoscopic evaluation, and should be sufficient to estimate the size of the primary (for T stage).
  2. Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations. Tonsillectomy or local excision of the primary without removal of nodal disease is permitted, as is excision removing gross nodal disease but with intact primary site. Limited neck dissections retrieving ≤ 4 nodes are permitted and considered as non-therapeutic nodal excisions.
  3. Immunohistochemical staining for p16 must be performed on tissue, and this tissue must be submitted for central review. Fine needle aspiration (FNA) biopsy specimens may be used as the sole diagnostic tissue if formalin-fixed paraffin-embedded cell block material is available for p16 immunohistochemistry. FNA specimens prepared with adequate p16 testing in this manner are acceptable to submit for central review. If the p16 preparation is not adequate, additional specimens will be required to establish p16 status. Centers are encouraged to contact the pathology chairs for clarification.
  4. Clinical stage T1-T2, N1-N2b or T3, N0-N2b (AJCC, 7th ed.) including no distant metastases based on the following diagnostic workup:

    • General history and physical examination within 56 days prior to registration;
    • Fiberoptic exam with laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) within 70 days prior to registration;
    • One of the following combinations of imaging is required within 56 days prior to registration:

      1. A computed tomography (CT) scan of the neck (with contrast) and a chest CT scan (with or without contrast);
      2. or an MRI of the neck (with contrast) and a chest CT scan (with or without contrast);
      3. or a CT scan of neck (with contrast) and a PET/CT of neck and chest (with or without contrast);
      4. or an MRI of the neck (with contrast) and a PET/CT of neck and chest (with or without contrast).

    Note: A CT scan of neck and/or a PET/CT performed for the purposes of radiation planning may serve as both staging and planning tools.

  5. Patients must provide their personal smoking history prior to registration. The lifetime cumulative history cannot exceed 10 pack-years. The following formula is used to calculate the pack-years during the periods of smoking in the patient's life; the cumulative total of the number of pack-years during each period of active smoking is the lifetime cumulative history.

    Number of pack-years = [Frequency of smoking (number of cigarettes per day) × duration of cigarette smoking (years)] / 20

    Note: Twenty cigarettes is considered equivalent to one pack. The effect of non-cigarette tobacco products on the survival of patients with p16-positive oropharyngeal cancers is undefined. While there are reportedly increased risks of head and neck cancer associated with sustained heavy cigar and pipe use (Wyss 2013), such sustained use of non-cigarette products is unusual and does not appear to convey added risk with synchronous cigarette smoking. Cigar and pipe tobacco consumption is therefore not included in calculating the lifetime pack-years. Marijuana consumption is likewise not considered in this calculation. There is no clear scientific evidence regarding the role of chewing tobacco-containing products in this disease, although this is possibly more concerning given the proximity of the oral cavity and oropharynx. In any case, investigators are discouraged from enrolling patients with a history of very sustained use (such as several years or more) of non-cigarette tobacco products alone.

  6. Zubrod Performance Status of 0-1 within 56 days prior to registration;
  7. Age ≥ 18;
  8. The trial is open to both genders;
  9. Adequate hematologic function within 14 days prior to registration, defined as follows:

    • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3;
    • Platelets ≥ 100,000 cells/mm3;
    • Hemoglobin (Hgb) ≥ 8.0 g/dl; Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.
  10. Adequate renal function within 14 days prior to registration, defined as follows:

    • Serum creatinine (Cr) < 1.5 mg/dl or creatinine clearance (CC) ≥ 50 ml/min determined by 24-hour collection or estimated by Cockcroft-Gault formula:

    • CC male = [(140 - age) x (wt in kg)] / [(Serum Cr mg/dl) x (72)]
    • CC female = 0.85 x (CC male)
  11. Adequate hepatic function within 14 days prior to registration defined as follows:

    • Bilirubin < 2 mg/dl;
    • Aspartate transaminase (AST) or alanine transaminase (ALT) < 3 x the upper limit of normal.
  12. Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential;
  13. Patients who are HIV positive but have no prior Acquired Immune Deficiency Syndrome (AIDS) -defining illness and have CD4 cells of at least 350/mm3 are eligible. HIV-positive patients must not have multi-drug resistant HIV infection or other concurrent AIDS-defining conditions. Patients must not be sero-positive for Hepatitis B (Hepatitis B surface antigen positive or anti-hepatitis B core antigen positive) or sero-positive for Hepatitis C (anti-Hepatitis C antibody positive). However, patients who are immune to hepatitis B (anti-Hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B).
  14. The patient must provide study-specific informed consent prior to study entry, including consent for mandatory submission of tissue for required, central p16 review.
  15. Patients who speak English (or read one of the languages for which a translation is available (see Section 10.2) must consent to complete the mandatory dysphagia-related patient reported instrument (MDADI). If the patient cannot understand spoken English and reads only languages not available in the MDADI translations, the patient can still participate in the trial, as this has been factored into the trial statistics. For all other patients, the MDADI is mandatory as it is included in the primary endpoint to be studied.

    Step 2: Randomization:

  16. p16 positive by immunohistochemistry (defined as greater than 70% strong nuclear or nuclear and cytoplasmic staining of tumor cells), confirmed by central pathology review; (see Section 10.1 for details).

Exclusion Criteria

Step 1: Registration:

  1. Cancers considered to be from an oral cavity site (oral tongue, floor mouth, alveolar ridge, buccal or lip), or the nasopharynx, hypopharynx, or larynx, even if p16 positive, or histologies of adenosquamous, verrucous, or spindle cell carcinomas;
  2. Carcinoma of the neck of unknown primary site origin (even if p16 positive);
  3. Radiographically matted nodes, defined as 3 abutting nodes with loss of the intervening fat plane;
  4. Supraclavicular nodes, defined as nodes visualized on the same axial imaging slice as the clavicle;
  5. Definitive clinical or radiologic evidence of metastatic disease or adenopathy below the clavicles;
  6. Gross total excision of both primary and nodal disease with curative intent; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease. In other words, to participate in this protocol, the patient must have clinically or radiographically evident gross disease for which disease response can be assessed.
  7. Patients with simultaneous primary cancers or separate bilateral primary tumor sites are excluded with the exception of patients with bilateral tonsil cancers;
  8. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible);
  9. Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable;
  10. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields;
  11. Severe, active co-morbidity defined as follows:

    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months;
    • Transmural myocardial infarction within the last 6 months;
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;
    • Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration;
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol other than those requested in Section 3.2.10.
    • Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition with immune compromise greater than that noted in Inclusion Criterion 13; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients.
  12. Pregnancy; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
  13. Prior allergic reaction to cisplatin.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Ireland,   Saudi Arabia,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02254278
Other Study ID Numbers  ICMJE NRG-HN002
NCI-2014-01279 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
NRG-HN002 ( Other Identifier: NRG Oncology )
NRG-HN002 ( Other Identifier: CTEP )
U10CA180868 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party NRG Oncology
Study Sponsor  ICMJE NRG Oncology
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Principal Investigator: Sue Yom NRG Oncology
PRS Account NRG Oncology
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP